Compare GSK plc (GSK) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? GSK plc trades at $46.65 (market cap $91.88B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.65 (market cap $141.25M). The key difference: GSK plc is far larger — about 650.5× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and GSK plc pays a 3.9% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days on average.
| GSK | KOLD | |
|---|---|---|
Market Cap | $91.88B | $141.25M |
Volume | 7,730,529 | 5,492,367 |
Sector | Health | Leveraged / Inverse |
52-Week High | $61.18 | $49.39 |
52-Week Low | $43.24 | $13.58 |
Typical Hold Time | 93 Days | 10 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
KOLD is trading at $24.475, down 1.47% on the day, with a bearish technical outlook as moving averages signal strong selling pressure. The stock faces headwinds from record-high natural gas production and mild weather forecasts that are weighing on energy sector sentiment. Recent news highlights geopolitical tensions in the Middle East and supply dynamics affecting natural gas markets, creating volatility for energy-related investments.
The outlook remains cautious given the bearish technical indicators and fundamental pressures from oversupply conditions in natural gas markets. Investment opportunities exist for contrarian investors betting on geopolitical risk premiums, but risks include continued production growth and weather-dependent demand uncertainty that could pressure energy sector performance in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
